UCARS 2026 - Session 1 - Myocardial Recovery - Evidence and implementation

Chairs: Josef Stehlik, MD, U of U; JB Durand, MD, MD Anderson; Rami Alharethi, MD, Intermountain

1. The “5th pillar” of GDMT: effective second line therapies or futile efforts increasing the risk of subsequent advanced therapies? — Vanessa Blumer, MD, Inova
2. Management of patients with HF Improved Ejection Fraction: knowns and unknowns. — Rob Mentz, MD, Duke
3. “Responders” and “non-responders” of HF therapies: should this be expected in a heterogeneous disease? How should clinicians, researchers and industry approach it? —  Andrew Ambrosy, MD, Kaiser Permanente Research Division, San Francisco